Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Director departure
Letter to company
Asset disposition
Appointed director
NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Resignation/termination of a director
07/28/2023 8-K Quarterly results
07/13/2023 8-K Resignation/termination of a director
Docs: "Press Release"
07/06/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Letter Agreement between Navidea Biopharmaceuticals, Inc. and John K. Scott, Jr",
"Press Release"
06/16/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Second Amendment to Asset Purchase Agreement between Cardinal Health 414, LLC and Navidea Biopharmaceuticals, Inc",
"[email protected]"
06/16/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Press Release (furnished pursuant to Item 7.01)"
05/25/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "Certificate of Designation of Preferences, Rights, Limitations and Restrictions of Series J Preferred Stock",
"Stock Purchase Agreement between Navidea Biopharmaceuticals, Inc. and Donald E. Garlikov",
"Stock Purchase Agreement between Navidea Biopharmaceuticals, Inc. and Irwin Bain",
"Press Release"
04/28/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Opinion of Maslon LLP",
"Common Stock Purchase Agreement between Navidea Biopharmaceuticals, Inc. and Keystone Capital Partners, LLC",
"Registration Rights Agreement between Navidea Biopharmaceuticals, Inc. and Keystone Capital Partners, LLC",
"Secured Bridge Note",
"First Amendment to Security Agreement between Navidea Biopharmaceuticals, Inc. and John Kim Scott, Jr",
"[email protected]"
04/13/2023 8-K Quarterly results
03/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation & Release Agreement effective March 30, 2023 between Navidea Biopharmaceuticals, Inc. and Michael Rosol",
"Consulting Services Agreement effective March 30, 2023 between Navidea Biopharmaceuticals, Inc. and G2G Ventures",
"Press release"
03/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/10/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex...
Docs: "First Amendment to Section 382 Rights Agreement between Navidea Biopharmaceuticals, Inc. and Continental Stock Transfer & Trust Company, LLC"
12/12/2022 8-K Quarterly results
11/15/2022 8-K Quarterly results
09/30/2022 8-K Quarterly results
09/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/02/2022 8-K Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive ...
Docs: "Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma",
"Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees"
05/12/2022 8-K Quarterly results
04/20/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Navidea Biopharmaceuticals, Inc. Valuation Report",
"Navidea Biopharmaceuticals Announces Updated Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis for U.S. and EU Markets",
"Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis"
04/12/2022 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs: "Certificate of Designation of Series H Junior Participating Preferred Stock of Navidea Biopharmaceuticals, Inc",
"Certificate of Designation of Voting Powers, Preferences, Limitations, Restrictions and Relative Rights of Series F Redeemable Convertible Preferred Stock",
"Certificate of Designation of Voting Powers, Preferences, Limitations, Restrictions and Relative Rights of Series G Redeemable Preferred Stock",
"Section 382 Rights Agreement, between Navidea Biopharmaceuticals, Inc. and Continental Stock Transfer & Trust Company, LLC, as Rights Agent",
"Stock Exchange and Loan Agreement between Investor and Navidea Biopharmaceuticals, Inc.",
"Secured Term Note",
"Security Agreement by Navidea Biopharmaceuticals, Inc. in favor of John Kim Scott, Jr",
"Registration Rights Agreement effective as of April 10, 2022 by and between Navidea Biopharmaceuticals, Inc. and John K. Scott, Jr",
"Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American",
"Navidea Biopharmaceuticals Announces Adoption of Plan Designed to Protect NOLs and Other Tax Assets, Closing of Bridge Loan Financing, and Business Update Q&A Series"
04/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Navidea Biopharmaceuticals Announces New Senior Regulatory Consultant and Return of Former Director of Regulatory Affairs"
03/23/2022 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results"
02/03/2022 8-K Quarterly results
12/16/2021 8-K Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive ...
Docs: "Navidea Biopharmaceuticals Terminates Stock Purchase Agreement",
"Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program",
"Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis"
12/13/2021 8-K Quarterly results
12/09/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results"
10/26/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Vice President of Operations"
10/14/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors"
09/30/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer"
09/17/2021 8-K Quarterly results
08/11/2021 8-K Quarterly results
Docs: "Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results"
07/13/2021 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Amendment to Stock Purchase Agreement and Letter of Investment Intent by and between the Company and Investor"
06/24/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy